Low bone mass

Reduce low bone mass with Preotact®

Osteoporosis is a disease in which bone mineral content is reduced resulting in low bone mass and increased risk of bone fracture. Osteoporosis affects around one in three women and one in five men around the world.

Preotact® is a new parathyroid hormone treatment for osteoporosis patients with low bone mass that can increase bone density and reduce bone fracture. Parathyroid hormone is an anabolic bone stimulating agent that can improve both the bone density and bone quality of patients with low bone mass.

Log in to learn more about treatment of low bone mass  

Nycomed

Nycomed is a European pharmaceutical company that has over 20 years’ experience of working with osteoporosis. Nycomed operates throughout Europe and in fast-growing markets in Latin America, Russia/CIS and Asia-Pacific.

Nycomed provides medicines and products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. Offering a broad portfolio of products in a wide range of therapeutic areas, particularly cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management.